Table 3

Transplant characteristics and outcomes.

Patient no.	Time from diagnosis to HSCT, mo	Type of donor	Conditioning regimen	Acute GVHD	Chronic GVHD	^a)Performance score before HSCT, %	^a)Performance score after HSCT, %	Disease status	Survival
1	12.2	URD	FluBuCy	No	No	50	90	CR	Alive
2	28.7	MSD	FluBuCy	No	Yes, limited	70	100	CR	Alive
3	4.8	MSD	FluBuCy	No	No	90	100	CR	Alive
4	7.4	MSD (syngeneic)	FluBuCyATG	No	No	70	-	NR	Dead (DOD)
5	5.4	URD	FluBuCyATG	Yes (Gr 2, skin)	No	90	100	CR	Alive
6	6.1	URD	FluBuCyATG	No	No	90	100	CR	Alive
7	3.1	MSD	FluBuCy ^b)VpATG	No	Yes, extensive	70	-	CR	Dead (TRM)
8	5.0	MSD	FluBuCy ^b)VpATG	No	No	90	100	CR	Alive
9	28.2	URD	FluBuCyATG	Yes (Gr 2, skin and gut)	No	70	80	CR	Alive

^a)Performance score was evaluated using the Lansky score, which was not provided to patients who died. ^b)Patients who developed HLH flare during conditioning received additional doses of VP-16 and dexamethasone.

Abbreviations: CR, complete response; DOD, death from disease; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; MSD, matched sibling donor; NA, not available; NR, nonresponse; PR, partial response; TRM, treatment-related mortality; URD, unrelated donor.

Blood Res 2022;57:152~157 https://doi.org/10.5045/br.2022.2022047